308 related articles for article (PubMed ID: 24128673)
1. Targeted cancer therapy--are the days of systemic chemotherapy numbered?
Joo WD; Visintin I; Mor G
Maturitas; 2013 Dec; 76(4):308-14. PubMed ID: 24128673
[TBL] [Abstract][Full Text] [Related]
2. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
3. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
Lumachi F; Chiara GB; Foltran L; Basso SM
Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Antibodies in Cancer Therapy.
Gasser M; Waaga-Gasser AM
Adv Exp Med Biol; 2016; 917():95-120. PubMed ID: 27236554
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy of metastatic breast cancer.
Sánchez-Muñoz A; Pérez-Ruiz E; Jiménez B; Ribelles N; Márquez A; García-Ríos I; Alba Conejo E
Clin Transl Oncol; 2009 Oct; 11(10):643-50. PubMed ID: 19828406
[TBL] [Abstract][Full Text] [Related]
6. A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE.
Hodeib M; Serna-Gallegos T; Tewari KS
Future Oncol; 2015; 11(23):3113-31. PubMed ID: 26597460
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
9. [Combination Therapy of Molecular-Targeted Drugs for Breast Cancer -- Their Potential in the Future].
Okano M; Ohtake T; Saji S
Gan To Kagaku Ryoho; 2016 Apr; 43(4):398-403. PubMed ID: 27220784
[TBL] [Abstract][Full Text] [Related]
10. [Current Status of Targeted Treatment in Breast Cancer].
Seiffert K; Schmalfeldt B; Müller V
Dtsch Med Wochenschr; 2017 Nov; 142(22):1669-1675. PubMed ID: 29078212
[TBL] [Abstract][Full Text] [Related]
11. Clinical trials and future potential of targeted therapy for ovarian cancer.
Itamochi H; Kigawa J
Int J Clin Oncol; 2012 Oct; 17(5):430-40. PubMed ID: 22926640
[TBL] [Abstract][Full Text] [Related]
12. Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
Galic V; Coleman RL; Herzog TJ
Curr Cancer Drug Targets; 2013 Jul; 13(6):698-707. PubMed ID: 23675882
[TBL] [Abstract][Full Text] [Related]
13. Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.
Vu T; Sliwkowski MX; Claret FX
Biochim Biophys Acta; 2014 Dec; 1846(2):353-65. PubMed ID: 25065528
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
de Melo Gagliato D; Jardim DL; Marchesi MS; Hortobagyi GN
Oncotarget; 2016 Sep; 7(39):64431-64446. PubMed ID: 26824988
[TBL] [Abstract][Full Text] [Related]
15. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
[TBL] [Abstract][Full Text] [Related]
16. Towards personalized treatment for early stage HER2-positive breast cancer.
Goutsouliak K; Veeraraghavan J; Sethunath V; De Angelis C; Osborne CK; Rimawi MF; Schiff R
Nat Rev Clin Oncol; 2020 Apr; 17(4):233-250. PubMed ID: 31836877
[TBL] [Abstract][Full Text] [Related]
17. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
Bashraheel SS; Domling A; Goda SK
Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.
Yu Q; Zhu Z; Liu Y; Zhang J; Li K
PLoS One; 2015; 10(5):e0127404. PubMed ID: 25993646
[TBL] [Abstract][Full Text] [Related]
19. Synthetic lethal approaches to breast cancer therapy.
Rehman FL; Lord CJ; Ashworth A
Nat Rev Clin Oncol; 2010 Dec; 7(12):718-24. PubMed ID: 20956981
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy in ovarian cancer.
Lim HJ; Ledger W
Womens Health (Lond); 2016 Jun; 12(3):363-78. PubMed ID: 27215391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]